Eli Lilly and Company (NYSE:LLY) Declares $1.30 Quarterly Dividend

by · The Cerbat Gem

Eli Lilly and Company (NYSE:LLY – Get Free Report) declared a quarterly dividend on Monday, October 28th, RTT News reports. Shareholders of record on Friday, November 15th will be paid a dividend of 1.30 per share on Tuesday, December 10th. This represents a $5.20 annualized dividend and a dividend yield of 0.58%.

Eli Lilly and Company has increased its dividend payment by an average of 15.2% annually over the last three years. Eli Lilly and Company has a payout ratio of 22.9% meaning its dividend is sufficiently covered by earnings. Equities research analysts expect Eli Lilly and Company to earn $24.24 per share next year, which means the company should continue to be able to cover its $5.20 annual dividend with an expected future payout ratio of 21.5%.

Eli Lilly and Company Price Performance

NYSE:LLY traded up $2.59 during trading hours on Monday, hitting $895.29. The company’s stock had a trading volume of 701,216 shares, compared to its average volume of 2,947,706. The company has a market capitalization of $850.89 billion, a PE ratio of 131.61, a PEG ratio of 3.24 and a beta of 0.42. Eli Lilly and Company has a 52-week low of $547.61 and a 52-week high of $972.53. The business’s 50-day moving average is $919.74 and its two-hundred day moving average is $863.20. The company has a debt-to-equity ratio of 1.74, a quick ratio of 0.87 and a current ratio of 1.11.

Eli Lilly and Company (NYSE:LLY – Get Free Report) last issued its quarterly earnings data on Thursday, August 8th. The company reported $3.92 earnings per share (EPS) for the quarter, topping the consensus estimate of $2.64 by $1.28. Eli Lilly and Company had a return on equity of 67.52% and a net margin of 18.86%. The firm had revenue of $11.30 billion during the quarter, compared to analysts’ expectations of $9.83 billion. As a group, research analysts anticipate that Eli Lilly and Company will post 14.05 EPS for the current fiscal year.

Wall Street Analysts Forecast Growth

LLY has been the subject of a number of analyst reports. Citigroup upped their price objective on shares of Eli Lilly and Company from $1,060.00 to $1,250.00 and gave the company a “buy” rating in a research note on Friday. Deutsche Bank Aktiengesellschaft restated a “buy” rating and set a $1,025.00 price objective on shares of Eli Lilly and Company in a report on Thursday, October 3rd. Berenberg Bank upped their target price on Eli Lilly and Company from $1,000.00 to $1,050.00 and gave the company a “buy” rating in a research note on Wednesday, August 14th. BMO Capital Markets raised their price target on Eli Lilly and Company from $1,001.00 to $1,101.00 and gave the stock an “outperform” rating in a research note on Friday, August 9th. Finally, Barclays upped their price objective on shares of Eli Lilly and Company from $913.00 to $1,025.00 and gave the company an “overweight” rating in a research note on Wednesday, July 10th. Three research analysts have rated the stock with a hold rating and seventeen have given a buy rating to the company. Based on data from MarketBeat, the company has an average rating of “Moderate Buy” and an average target price of $1,013.41.

View Our Latest Analysis on Eli Lilly and Company

Eli Lilly and Company Company Profile

(Get Free Report)

Eli Lilly and Company discovers, develops, and markets human pharmaceuticals worldwide. The company offers Basaglar, Humalog, Humalog Mix 75/25, Humalog U-100, Humalog U-200, Humalog Mix 50/50, insulin lispro, insulin lispro protamine, insulin lispro mix 75/25, Humulin, Humulin 70/30, Humulin N, Humulin R, and Humulin U-500 for diabetes; Jardiance, Mounjaro, and Trulicity for type 2 diabetes; and Zepbound for obesity.

Read More